Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. on February 3, 2023. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Atlanta, GA. Its common stock trades on the Nasdaq Capital Market under the symbol "ALZN".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing matter rather than financial performance data.
Material Changes and Listing Status
On January 30, 2023, the Company received a Deficiency Letter from the Nasdaq Listing Qualifications Staff. The notice states that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for its common stock closed below $1.00 per share for 30 consecutive business days.
- Compliance Deadline: The Company has 180 calendar days, until July 31, 2023, to regain compliance.
- Requirement: The bid price must close at $1.00 or more for a minimum of 10 consecutive business days during the compliance period.
- Current Status: The deficiency has no immediate effect on the listing; the stock continues to trade on the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the closing bid price and may evaluate options to resolve the deficiency, including a potential reverse stock split if necessary. The Company notes that if it fails to regain compliance by July 31, 2023, it may be eligible for an additional 180-day compliance period if it meets other listing standards (such as market value of publicly held shares) and provides written notice of intent to cure.
Risks: There is no assurance that the Company will be able to regain compliance with the Minimum Bid Price or maintain compliance with other Nasdaq listing standards. Failure to cure the deficiency could result in delisting, though the Company retains the right to appeal such a determination to a Nasdaq hearings panel.
Key Facts for Investor Verification
- Verify the current trading price of ALZN to assess the likelihood of meeting the $1.00 minimum bid price requirement.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to address the deficiency.
- Check for any subsequent correspondence from Nasdaq regarding the Company's compliance status or potential delisting notices.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the initial deadline is missed.